<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01130584</url>
  </required_header>
  <id_info>
    <org_study_id>PK01/02/10</org_study_id>
    <nct_id>NCT01130584</nct_id>
  </id_info>
  <brief_title>Pyruvate Kinase Isoform M2 (PKM2) as a Possible Biomarker for Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if pyruvate kinase M2 (PKM2) can be used as a
      biomarker in cancer.

      Pyruvate kinase M2 is more elevated in malignant pleural fluid than in plasma, and may be a
      useful biomarker to distinguish between malignant and non-malignant causes of pleural
      effusion. In addition, pyruvate kinase M2 has also been found to be elevated in saliva in
      cancer patients compared to controls. Measuring pyruvate kinase M2 in saliva may be used to
      diagnose cancer or monitor the treatment progress of cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Cancer patient</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pyruvate kinase isoform M2</intervention_name>
    <arm_group_label>Cancer patient</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any cancer patient
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any cancer patient with pleural effusion that is being drained through an indwelling
             chest-tube in an inpatient ward.

        Exclusion Criteria:

          -  Patient with a pleural effusion who does not have proven cancer or whose pleural
             effusion is not known to be malignant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National University Hospital, Singapore</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Elia S, Massoud R, Guggino G, Cristino B, Cortese C, De Massimi AR, Zenobi R. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures. Eur J Cardiothorac Surg. 2008 Apr;33(4):723-7. doi: 10.1016/j.ejcts.2008.01.014. Epub 2008 Feb 7.</citation>
    <PMID>18261916</PMID>
  </reference>
  <reference>
    <citation>Mazurek S. Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours. Ernst Schering Found Symp Proc. 2007;(4):99-124. Review.</citation>
    <PMID>18811055</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2010</study_first_submitted>
  <study_first_submitted_qc>May 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2010</study_first_posted>
  <last_update_submitted>December 10, 2013</last_update_submitted>
  <last_update_submitted_qc>December 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2013</last_update_posted>
  <keyword>Cancer Patients</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

